Skip to main content
2023 BMES Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Shih-Ting Wang, PhD (she/her/hers)

Postdoctoral Associate
Massachusetts Institute of Technology
Cambridge, Massachusetts, United States

My name is Shih-Ting (Christine) Wang, and I am a postdoctoral associate in the Koch Institute of MIT. I am a biomaterials engineer designing and engineering novel materials with well-defined sequence, structure, and properties that can interact with biological systems at multi-scales. My academic training and research experience have provided me with an interdisciplinary background with expertise in both materials and biological disciplines. I am currently a faculty candidate looking to build on my works to develop enabling biotechnologies that can tackle unmet needs in early disease diagnosis and treatment.
My PhD thesis research at Imperial College London studied the self-assembly of peptides derived from amyloid proteins in type 2 diabetes. My work used peptide synthesis to identify key amino acids that drive fibrillation propensity and polymorphism of amyloids in solution and in the presence of nanoparticle surfaces. After completing my Ph.D., I conducted postdoctoral research at Brookhaven National Laboratory, engineering DNA self-assembly to build programmable protein lattices. My work tackled a challenge in protein organization for crystallography, by the design of DNA origamis to encapsulate proteins and build programmble lattices. These systems have potentials to understand protein stability and function in confined space and develop cell-free systems for protein storage and substrate selections, which I am eager to explore further. My current research at MIT develops clinically translatable nano-sensors for lung cancer and infection. My work focuses on non-invasive breath biopsy, where I engineer multiplexed nanosensors that can sense aberrant proteolytic activities in disease microenvironments and release biocompatible, synthetic volatile reporters detectable in the exhaled breath. Such a platform enables longitudinal monitoring of tumor progression and treatment responses in mouse models, with the hope of integrating with existing screening and imaging practices to achieve precision diagnostics for early diagnosis of cancer and guide treatment decisions to increase patient survival.

Presentation(s):

Email Shih-Ting